Kisseberth, W. C., D. M. Vail, et al. (2008). “Phase I clinical evaluation of carboplatin in tumor-bearing cats: a veterinary cooperative oncology group study.” J Vet Intern Med 22(1): 83-8.
Carboplatin (Paraplatin, Bristol-Myers Squibb) is an alkylating agent widely used as chemotherapy for certain tumors in humans and dogs. In cats, only isolated case reports exist. Little investigation has been done to investigate the optimal dose and efficacy of this drug in cats with tumors. In this study, 59 cats with naturally occurring solid tumors were treated with carboplatin. Cats were enrolled in the study from several different institutions and had various tumor types, such as injection-site sarcomas and oral squamous cell sarcomas. The starting dose was 160 mg/m(2) of body surface area and the dose was increased in cohorts of cats until the maximally tolerated dose was determined. The maximally tolerated dose was 240 mg/m(2) and the dose limiting toxicity was neutropenia. The lowest neutrophil and platelet counts occurred 2 to 3 weeks after drug administration. There was no evidence of drug-induced kidney toxicity or pulmonary edema. There was one cat with complete response to treatment, and six cats with partial responses. The dose of carboplatin recommended by the researchers is 240 mg/m(2) IV every 3 to 4 weeks. Carboplatin appears to be safe and well tolerated in cats.
>> PubMed abstract